These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 25040895)

  • 1. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France.
    Cacoub P; Dabis F; Costagliola D; Almeida K; Lert F; Piroth L; Semaille C
    Liver Int; 2015 Jan; 35(1):65-70. PubMed ID: 25040895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia.
    Ye S; Pang L; Wang X; Liu Z
    Curr HIV/AIDS Rep; 2014 Jun; 11(2):128-33. PubMed ID: 24682917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceived risk for severe outcomes and drinking status among drug users with HIV and Hepatitis C Virus (HCV).
    Elliott JC; Hasin DS; Des Jarlais DC
    Addict Behav; 2016 Dec; 63():57-62. PubMed ID: 27423099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.
    Shaheen MA; Idrees M
    World J Hepatol; 2015 Mar; 7(3):616-27. PubMed ID: 25848486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Co-infection in People Living With HIV-Epidemiologic Differences Between Men Who Have Sex With Men MSM and Non-MSM.
    Kwan TH; Wong BCK; Wong KH; Lee SS
    Front Public Health; 2022; 10():925600. PubMed ID: 35719672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data).
    Barré T; Mercié P; Lions C; Miailhes P; Zucman D; Aumaître H; Esterle L; Sogni P; Carrieri P; Salmon-Céron D; Marcellin F;
    AIDS Res Ther; 2022 Mar; 19(1):15. PubMed ID: 35292069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of hepatitis C epidemic among people living with HIV in Estonia based on Estonian HIV cohort study.
    Kase K; Avi R; Toompere K; Rajasaar H; Pauskar M; Soodla P; Jõgeda EL; Zilmer K; Lutsar I; Huik K
    BMC Infect Dis; 2021 Aug; 21(1):792. PubMed ID: 34376170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.
    Mason LM; Duffell E; Veldhuijzen IK; Petriti U; Bunge EM; Tavoschi L
    Euro Surveill; 2019 Jul; 24(30):. PubMed ID: 31362808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of renal involvement in cryoglobulinaemia: a retrospective study of 153 patients.
    Coliche V; Sarda MN; Laville M; Chapurlat R; Rheims S; Sève P; Théry-Casari C; Lega JC; Fouque D
    Clin Kidney J; 2019 Jun; 12(3):365-372. PubMed ID: 31198536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.
    Ndjoyi-Mbiguino A; Kombe Kombe AJ; Bivigou-Mboumba B; Zoa-Assoumou S; Akombi FL; Nzengui Nzengui F; M'boyis Kamdem H; François-Souquière S
    PLoS One; 2018; 13(1):e0190529. PubMed ID: 29385148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
    Garimella T; Tao X; Sims K; Chang YT; Rana J; Myers E; Wind-Rotolo M; Bhatnagar R; Eley T; LaCreta F; AbuTarif M
    Drugs R D; 2018 Mar; 18(1):55-65. PubMed ID: 29255971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
    Lacombe K; Fontaine H; Dhiver C; Metivier S; Rosenthal E; Antonini T; Valantin MA; Miailhes P; Harent S; Batisse D; Pageaux GP; Chas J; Aumaitre H; Dominguez S; Allegre T; Lafeuillade A; Billaud E; De Truchis P; Perre P; Leroy V; De Ledinghen V; Sogni P; Dabis F; Zhao Y; Filipovics A; Fedchuk L; Akremi R; Bennai Y; Salmon Ceron D
    J Acquir Immune Defic Syndr; 2017 May; 75(1):97-107. PubMed ID: 28272163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of factors associated with the quality of life of patients living with HIV/HCV co-infection.
    Pereira M; Fialho R
    J Behav Med; 2016 Oct; 39(5):767-81. PubMed ID: 27506910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C treatment initiation in HIV-HCV coinfected patients.
    Cotte L; Pugliese P; Valantin MA; Cuzin L; Billaud E; Duvivier C; Naqvi A; Cheret A; Rey D; Pradat P; Poizot-Martin I;
    BMC Infect Dis; 2016 Jul; 16():345. PubMed ID: 27450098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
    Scheiner B; Schwabl P; Steiner S; Bucsics T; Chromy D; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T; Mandorfer M
    Medicine (Baltimore); 2016 Jul; 95(27):e4061. PubMed ID: 27399090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of HIV/HCV coinfection.
    Mandorfer M; Schwabl P; Steiner S; Reiberger T; Peck-Radosavljevic M
    Hepatol Int; 2016 May; 10(3):424-35. PubMed ID: 26758592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
    Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.
    Poizot-Martin I; Naqvi A; Obry-Roguet V; Valantin MA; Cuzin L; Billaud E; Cheret A; Rey D; Jacomet C; Duvivier C; Pugliese P; Pradat P; Cotte L;
    PLoS One; 2015; 10(10):e0141164. PubMed ID: 26488159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.
    Ruta S; Cernescu C
    World J Gastroenterol; 2015 Oct; 21(38):10811-23. PubMed ID: 26478672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.